Skip to main content

Opera Bioscience

Opera Bioscience utilizes a microbial platform to produce high-purity, soluble recombinant proteins without the complications of inclusion bodies or extensive purification processes. This approach significantly reduces costs and time for researchers by providing affordable, animal-free reagents and materials essential for biomanufacturing.

Traction 6/10
Chicago, United States · HQ
Founded 202131K+ followers
  • Biotechnology
Updated 23 months ago

Funding

Raised to date

$150KRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

1 founder

Gerry Sapienza

Chief Executive Officer

Product

Problem

Recombinant protein production often suffers from low yields, misfolding, and the formation of insoluble inclusion bodies, necessitating complex and costly purification processes. Traditional methods also rely on animal-derived components, raising ethical and safety concerns for biomanufacturing applications.

Solution

Opera Bioscience offers a microbial protein expression platform that secretes high-purity, soluble, and correctly folded recombinant proteins directly from the cell, eliminating the need for extensive purification. This single-step secretion process avoids inclusion bodies, reduces endotoxin contamination, and simplifies downstream processing. The platform enables high yields of proteins, enzymes, and growth factors that are typically difficult to express in microbial systems. By providing affordable, animal-free reagents, Opera Bioscience aims to make biomanufacturing more accessible and sustainable.

Target Audience

The primary customers are researchers and biomanufacturers seeking affordable, high-quality, and animal-free recombinant proteins for various applications.

Features

  • Microbial platform for direct secretion of soluble, high-purity recombinant proteins
  • Avoidance of inclusion bodies and reduced endotoxin levels compared to traditional methods
  • Animal-free production process for ethical and safe biomanufacturing
  • High yields of difficult-to-express proteins, enzymes, and growth factors
  • Simplified downstream processing with minimal purification requirements
This profile is AI-generated and may contain inaccuracies.